Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capivasertib - AstraZeneca

Next Previous
Drug Profile

Capivasertib - AstraZeneca

Alternative Names: AZD 5363; Truqap

Latest Information Update: 09 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Therapeutics; Cancer Research Technology; The Institute of Cancer Research
  • Developer AstraZeneca
  • Class Antineoplastics; Piperidines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Proto-oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HER2 negative breast cancer
  • Phase III Prostate cancer; Triple negative breast cancer
  • Phase II Breast cancer; Endometrial cancer; Gastric cancer; Meningioma; Non-Hodgkin's lymphoma
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Preclinical Diffuse large B cell lymphoma
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 29 Apr 2025 Registered for HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Second-line therapy ad greater, Metastatic disease) in China
  • 29 Apr 2025 Efficacy and adverse event data from a phase III trial in Prostate cancer released by AstraZeneca
  • 29 Apr 2025 AstraZeneca terminates phase III trial in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in Netherlands, US, Australia, Belgium, Brazil, Canada, Chile, China, Czechia, France, Greece, Hungary, India, Japan, Korea, Mexico, Poland, Spain, Taiwan, UK, Israel and Turkey due to futility (PO) (NCT05348577)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top